Mucomyst (Acetylcysteine)

Mucomyst is a mucolytic that acts on respiratory secretions to facilitate clearance in several chronic and acute conditions.

• Chronic bronchopulmonary diseases (e.g., COPD, chronic bronchitis): improves mucus clearance and eases breathing.
• Cystic fibrosis: helps liquefy thick secretions, supporting airway hygiene.
• Exposure to irritant gases (e.g., chlorine, ammonia): reduces risk of bronchospasm by thinning airway mucus.

• Acetylcysteine cleaves disulfide bonds within mucus glycoproteins, lowering the viscoelasticity of secretions and promoting their transport out of the airways. It also serves as a precursor for intracellular glutathione synthesis, enhancing antioxidant defenses in the respiratory epithelium.

Acetylcysteine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Cough or throat irritation during inhalation.
• Bronchospasm, especially in patients with reactive airways.
• Nausea or mild gastrointestinal discomfort.
• Unpleasant taste or odor.
• Headache.
• Mild dizziness.

Serious or Rare Side Effects

• Anaphylactic reaction or severe hypersensitivity.
• Severe bronchospasm requiring medical intervention.
• Angioedema involving face or airway.
• Pulmonary edema.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Significant hypotension.

Before initiating Mucomyst, clinicians should consider several safety measures.

• Assess airway reactivity: perform bronchial provocation testing in patients with known asthma.
• Monitor for bronchospasm: observe the patient during the first inhalation session.
• Avoid in individuals with documented hypersensitivity to acetylcysteine or its excipients.
• Use cautiously in patients with active peptic ulcer disease, as irritation may be increased.
• Pregnancy and lactation: consult the prescriber because safety data are limited.
• Store at room temperature: keep in the original container, protect from moisture and light.

Acetylcysteine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Nitroglycerin: concurrent use may precipitate severe hypotension.
• Activated charcoal: can reduce drug absorption if administered orally.

Moderate Interactions (Monitor Closely)

• Bronchodilators: may increase the risk of bronchospasm in hyperreactive airways.
• Other mucolytics: additive irritation of the respiratory tract.
• Anticoagulants: potential for enhanced bleeding tendency, requiring monitoring of coagulation parameters.